Ibex Wealth Advisors Buys 1,610 Shares of AbbVie Inc. $ABBV

Ibex Wealth Advisors lifted its stake in AbbVie Inc. (NYSE:ABBV) by 2.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 58,426 shares of the company’s stock after buying an additional 1,610 shares during the period. AbbVie comprises 1.2% of Ibex Wealth Advisors’ portfolio, making the stock its 24th biggest holding. Ibex Wealth Advisors’ holdings in AbbVie were worth $10,845,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vise Technologies Inc. acquired a new position in shares of AbbVie in the second quarter valued at $8,615,000. Allworth Financial LP increased its holdings in AbbVie by 43.4% in the 2nd quarter. Allworth Financial LP now owns 213,710 shares of the company’s stock valued at $39,669,000 after buying an additional 64,685 shares during the period. Addison Advisors LLC raised its stake in shares of AbbVie by 1.3% in the 2nd quarter. Addison Advisors LLC now owns 4,729 shares of the company’s stock valued at $878,000 after buying an additional 60 shares in the last quarter. Tillman Hartley LLC lifted its holdings in shares of AbbVie by 5.2% during the 2nd quarter. Tillman Hartley LLC now owns 3,246 shares of the company’s stock worth $603,000 after acquiring an additional 160 shares during the period. Finally, Americana Partners LLC lifted its holdings in shares of AbbVie by 0.6% during the 2nd quarter. Americana Partners LLC now owns 271,762 shares of the company’s stock worth $50,445,000 after acquiring an additional 1,592 shares during the period. 70.23% of the stock is currently owned by institutional investors.

Insider Buying and Selling at AbbVie

In related news, EVP Azita Saleki-Gerhardt sold 42,370 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $198.42, for a total value of $8,407,055.40. Following the completion of the sale, the executive vice president owned 177,292 shares in the company, valued at $35,178,278.64. This represents a 19.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.25% of the stock is currently owned by corporate insiders.

AbbVie Stock Performance

AbbVie stock opened at $218.92 on Monday. The company’s 50-day moving average is $223.24 and its two-hundred day moving average is $202.67. The company has a market cap of $386.92 billion, a PE ratio of 104.25, a PEG ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $244.81. The company has a current ratio of 0.74, a quick ratio of 0.61 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period last year, the company earned $3.00 EPS. The firm’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Analyst Ratings Changes

ABBV has been the subject of several recent research reports. UBS Group increased their price target on shares of AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday. Wall Street Zen raised AbbVie from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Hsbc Global Res cut AbbVie from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 1st. Finally, Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the company from $170.00 to $270.00 in a research note on Wednesday, September 17th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $236.57.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.